Kostas Zervas

Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single‐centre experience in 303 patients

Kostas Zervas, Evgenia Verrou, Zisis Teleioudis et al. · British Journal of Haematology · 2006 · 296 citations

Bone Disease, Zoledronic Acid, Bone Health +12

Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐<i>κ</i>B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

Evangelos Terpos, Deborah J. Heath, Amin Rahemtulla et al. · British Journal of Haematology · 2006 · 219 citations · Full text

Sclerostin, Relapsed Multiple Myeloma, Immunology +17

Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma

Ashraf Badros, Evangelos Terpos, Eirini Katodritou et al. · Journal of Clinical Oncology · 2008 · 144 citations · Full text

Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

Eirini Katodritou, Evangelos Terpos, Charikleia Kelaïdi et al. · American Journal of Hematology · 2013 · 68 citations · Full text

Hematological Malignancy, Bortezomib‐based Regimens, Transplantation +15

Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?

Eirini Katodritou, Vassiliki Gastari, Evgenia Verrou et al. · Leukemia Research · 2009 · 48 citations

Hematological Malignancy, Medicine, Unusual Locations +7